You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
News on CRISPR, gene editing, RNAi in genetics, genomics, and molecular diagnostics.
G+FLAS said it provides CRISPR-related research services, tools, and reagents and applies CRISPR technology to develop drugs and produce genome-edited plants.
The method could be used to determine the function of thousands of mutations to see whether they cause disease, or confer drug sensitivity or resistance.
ZeClinics said it will use the CRISPR-Cas9 technology to create various zebrafish knockout variants for use as disease models.
The gift from philanthropists Allen and Charlotte Ginsburg will support a new center within UCLA's Institute for Precision Health and a patient clinic.
Researchers used CRISPR to reintroduce an archaic variant of NOVA1 into cortical organoids to study how a human-specific variant may have affected evolution.
Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.
Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.
Science reports that a Dutch research funding agency is combating a ransomware attack.
In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.
The growth of next-generation sequencing (NGS) testing presents both opportunities and challenges for clinical, informatics, and laboratory teams.
In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.
This webinar, the first in a “Women in Single Cell” series sponsored by Mission Bio, will discuss the use of single-cell analysis to assess genome editing for use in pre-clinical disease modeling.